Group 1 - The stock price of Jindalai (688057) closed at 12.65 yuan on January 9, 2026, reflecting a 3.52% increase from the previous week's price of 12.22 yuan [1] - The highest intraday price for Jindalai on January 9 was 12.71 yuan, while the lowest intraday price on January 5 was 12.23 yuan [1] - Jindalai's current total market capitalization is 3.491 billion yuan, ranking 70th out of 106 in the environmental governance sector and 4329th out of 5182 in the A-share market [1] Group 2 - The company plans to invest 280 million yuan in Jici Medical, acquiring a 34.00% stake, focusing on autologous cell technology research and development [2] - Jindalai is also increasing its investment in Zhongke Hongtai to enter the vascular interventional surgical robot field, with products currently undergoing special review procedures for national innovative medical devices [2]

天眼查App显示，近日，中蛇端粒再生健康科技（湖南）有限公司成立，法定代表人为田杰，注册资本 500万人民币，经营范围为许可项目：食品销售;茶叶制品生产;酒类经营;酒制品生产（依法须经批准的 项目，经相关部门批准后方可开展经营活动，具体经营项目以批准文件或许可证件为准）一般项目：健 康咨询服务（不含诊疗服务）;细胞技术研发和应用;人体干细胞技术开发和应用;技术服务、技术开发、 技术咨询、技术交流、技术转让、技术推广;工程和技术研究和试验发展;宠物服务（不含动物诊疗）;会 议及展览服务;远程健康管理服务;体育健康服务;人工智能行业应用系统集成服务;娱乐性展览;食用农产 品零售;食用农产品批发;食用农产品初加工;生物化工产品技术研发;互联网销售（除销售需要许可的商 品）;保健食品（预包装）销售;生物饲料研发;食品销售（仅销售预包装食品）;农副产品销售;茶具销售; 品牌管理;市场营销策划;企业管理;日用百货销售;二手日用百货销售;普通货物仓储服务（不含危险化学 品等需许可审批的项目）;食品互联网销售（仅销售预包装食品）;第一类医疗器械销售;广告设计、代 理;广告发布;化妆品零售;业务培训（不含教育培训、职业技能培训 ...

Core Insights - Lianyungang Tongyuan Cell Gene Engineering Co., Ltd. has been established with a registered capital of 3 million RMB, fully owned by Tongyuan Pathology Diagnosis Center (Jiangsu) Co., Ltd. [1] Company Overview - The legal representative of the company is Pan Jiagan [1] - The company is classified under the scientific research and technical service industry, specifically in engineering and technical research and development [1] - The business address is located at No. 567 Huaguoshan Avenue, Building 5, 6th Floor, China Medicine Port, Lianyungang Economic and Technological Development Zone [1] Business Scope - The company's business scope includes medical beauty services, life beauty services, drug clinical trial services, cosmetics production, leasing of Class III medical equipment, and operation of Class III medical devices [1] - It also involves cell technology research and application, engineering and technical research and experimental development, human stem cell technology development and application, and various technical services [1] - Additional services include internet data services, big data services, and sales of medical devices and cosmetics [1]

Group 1 - Shandong Mingxiang Biotechnology Co., Ltd. has been established with a registered capital of 10 million yuan, focusing on biomass energy technology services and comprehensive utilization of agricultural and forestry waste [1][2] - The company is co-owned by He Feng Food Co., Ltd. (35% share), Yafang New Ge Feng Agricultural Technology Co., Ltd. (35% share), and Pufang He Guangyuan Animal Health Co., Ltd. (30% share) [3] - The business scope includes cell technology research and application, livestock and fishery feed sales, and animal health monitoring [2][3] Group 2 - The company is located in Gaomi City, Shandong Province, and is registered under the High-Mi City Market Supervision Administration [2] - The operational period of the company is set until July 30, 2025, with no fixed expiration date [2] - The company is classified under the scientific research and technical services industry [2]

Core Viewpoint - Sartorius has expanded its cell technology product line by integrating MatTek into its laboratory products and services division, creating synergies with existing drug development solutions, including cell analysis instruments, reagents, and AI models [1][2]. Group 1: Acquisition Details - Sartorius officially completed the acquisition of MatTek, a subsidiary of BICO Group, on July 1, 2025 [2]. - The acquisition aims to enhance Sartorius's capabilities in cell technology and drug development [2]. Group 2: MatTek Overview - MatTek is a leading developer and manufacturer of human cell microtissues and three-dimensional models, focused on accelerating drug development processes [3]. - The advanced cell models developed by MatTek simulate the structure and function of human tissues, providing more accurate, cost-effective, and reproducible results compared to traditional two-dimensional cell cultures, while also reducing the need for animal testing [3]. - MatTek employs over 80 staff and is headquartered in Ashland, Massachusetts, with a production facility in Bratislava, Slovakia [3].